← Leaderboards
Yun Guan
Johns Hopkins University
$12,204,762
Attributed
$15,750,213
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,750,213 · 8
By mechanism
R01$10,740,192 · 5
RF1$4,560,854 · 2
R21$449,167 · 1
Top collaborators
- Sridevi V. Sarma5 shared
- Xu Cao2 shared
- Zhaozhu Qiu1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Yuan-Xiang Tao$12,887,850
- Zhaozhu Qiu$7,994,953
- Amanda Helen Klein$3,668,673
- David L Huso$2,555,100
- Gene Yevgeny Fridman$6,162,955
Others in their field
Top investigators on “Neurons”
- Hongkui Zeng · Allen Institute$106,358,289
- Eric Martin McDade · Washington University$94,632,845
- Ed Lein · Allen Institute$90,858,363
- Randall J Bateman · Washington University$65,841,935
- John Morris · Washington University$65,018,684
- Paul S. Aisen · Cognition Therapeutics, Inc.$58,570,460
Research focus
NeuronsPainIn VivoPharmaceutical PreparationsRattusNerve InjuryPain InhibitionPainful NeuropathyAttenuatedInjurySpinal CordAdverse EffectsMediatingNociceptionPain ManagementResponseSide EffectBiologicalAfferent NeuronsReceptorFuturePathway InteractionsSpinalAnimals
Grant awards (30)
CRCNS: Computational Model of Chronic Pain Analgesia via Closed-Loop Peripheral Nerve Stimulation$335,514
R01 · FY2025 · AT
Birth Tissue Products for Non-opioid Treatment of Post-surgical Pain$625,560
R01 · FY2024 · NS · contact PI
Subchondral Bone Cavities in Osteoarthritis Pain$620,588
R01 · FY2024 · AG
Mechanistic Study of Pain Inhibition by Activation of Non-nociceptive Afferent Fibers$460,563
R01 · FY2024 · NS · contact PI
CRCNS: Computational Model of Chronic Pain Analgesia via Closed-Loop Peripheral Nerve Stimulation$374,699
R01 · FY2024 · AT
Validation of a new large-pore channel as a novel target for neuropathic pain$2,039,202
RF1 · FY2023 · NS
CRCNS: Computational Model of Chronic Pain Analgesia via Closed-Loop Peripheral Nerve Stimulation$390,028
R01 · FY2023 · AT
Birth Tissue Products for Non-opioid Treatment of Post-surgical Pain$1
R01 · FY2023 · NS · contact PI
Birth Tissue Products for Non-opioid Treatment of Post-surgical Pain$644,907
R01 · FY2022 · NS · contact PI
Mechanistic Study of Pain Inhibition by Activation of Non-nociceptive Afferent Fibers$481,253
R01 · FY2022 · NS · contact PI
CRCNS: Computational Model of Chronic Pain Analgesia via Closed-Loop Peripheral Nerve Stimulation$399,845
R01 · FY2022 · AT
Birth Tissue Products for Non-opioid Treatment of Post-surgical Pain$644,907
R01 · FY2021 · NS · contact PI
Mechanistic Study of Pain Inhibition by Activation of Non-nociceptive Afferent Fibers$487,574
R01 · FY2021 · NS · contact PI
CRCNS: Computational Model of Chronic Pain Analgesia via Closed-Loop Peripheral Nerve Stimulation$409,375
R01 · FY2021 · AT
Subchondral Bone Cavities in Osteoarthritis Pain$2,521,652
RF1 · FY2020 · AG
Birth Tissue Products for Non-opioid Treatment of Post-surgical Pain$660,845
R01 · FY2020 · NS · contact PI
Mechanistic Study of Pain Inhibition by Activation of Non-nociceptive Afferent Fibers$493,773
R01 · FY2020 · NS · contact PI
Mrgs as New Target for the Treatment of Neuropathic Pain$358,203
R01 · FY2020 · NS · contact PI
Mechanistic Study of Pain Inhibition by Activation of Non-nociceptive Afferent Fibers$499,847
R01 · FY2019 · NS · contact PI
Mrgs as New Target for the Treatment of Neuropathic Pain$358,203
R01 · FY2019 · NS · contact PI
Mrgs as New Target for the Treatment of Neuropathic Pain$358,203
R01 · FY2018 · NS · contact PI
Mrgs as New Target for the Treatment of Neuropathic Pain$357,656
R01 · FY2017 · NS · contact PI
Developing Novel Direct Current Stimulation Technology for Safe Precision Pain Treatment$245,313
R21 · FY2017 · NS · contact PI
Mrgs as New Target for the Treatment of Neuropathic Pain$356,563
R01 · FY2016 · NS · contact PI
Developing Novel Direct Current Stimulation Technology for Safe Precision Pain Treatment$203,854
R21 · FY2016 · NS · contact PI
MrgprC, A New Target for the Treatment of Neuropathic Pain$287,000
R01 · FY2015 · NS · contact PI
MrgprC, A New Target for the Treatment of Neuropathic Pain$284,130
R01 · FY2014 · NS · contact PI
MrgprC, A New Target for the Treatment of Neuropathic Pain$276,955
R01 · FY2013 · NS · contact PI
MrgprC, A New Target for the Treatment of Neuropathic Pain$287,000
R01 · FY2012 · NS · contact PI
MrgprC, A New Target for the Treatment of Neuropathic Pain$287,000
R01 · FY2011 · NS · contact PI